This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $790,000.00 in funding to the Regents of the University of Minnesota to conduct research on the immune response and neurological effects of West Nile virus (WNV) infection. The goal is to gain a deeper molecular understanding of WNV neuroinvasion, CNS immunity, and the persistent inflammatory sequelae that can result from WNV encephalitis. The research will employ newly developed mouse models, recombinant forms of WNV, and advanced single-cell and spatial transcriptomic/epigenomic techniques to address critical knowledge gaps. The findings are expected to inform efforts to mitigate and ameliorate the severe neurological consequences of WNV infection in human patients. The award period runs from Sep 3, 2024 to Aug 31, 2029.
Generated 1/28/25, 7:35 AM